Your PFAS Numbers: What Blood Tests Mean and How to Respond
PFAS blood testing—measuring the concentrations of individual PFAS compounds in serum—is moving from research tool to clinical application as awareness of PFAS health effects grows and as some clinical laboratories offer PFAS panels as part of environmental health assessments. For individuals who have been exposed to PFAS-contaminated water, lived near industrial sources, or worked in PFAS-intensive occupations, understanding their personal PFAS body burden and its health implications is an increasingly reasonable clinical objective. But the translation from laboratory result to clinical action requires navigating significant scientific uncertainty about PFAS dose-response relationships and the efficacy of available interventions for reducing body burden.
What PFAS Blood Test Results Mean
Serum PFAS concentrations—measured by mass spectrometry in specialized environmental health laboratories—provide a snapshot of an individual’s current PFAS body burden, reflecting the accumulated balance between past PFAS exposures and biological elimination over preceding months to years (depending on the PFAS compound’s half-life). Results are typically reported in nanograms per milliliter (ng/mL) or nanograms per gram of serum (ng/g). Reference range comparison—comparing an individual’s PFAS levels to population distributions from nationally representative surveys like NHANES—contextualizes whether a given result is elevated relative to peers, but does not directly indicate health risk, as population-scale body burdens may themselves be above health-optimal levels.
Clinical interpretation of PFAS results requires understanding which PFAS compounds are measured (different panels vary in the specific PFAS included), the laboratory’s quality control and reporting thresholds, and the health outcome evidence base for the specific compounds at the concentrations detected. No universally agreed clinical reference values currently define “safe” versus “concerning” PFAS blood levels with the same regulatory basis as cholesterol or blood pressure targets—though academic clinical guidelines are emerging from occupational medicine and environmental health specialty organizations.
Body Burden Reduction: What Actually Works
PFAS body burden is reduced by eliminating ongoing exposures and allowing biological elimination pathways to clear accumulated PFAS over time. Effective exposure reduction strategies include: replacing PFAS-contaminated drinking water with certified filtered water (most important for communities with PFAS water contamination); reducing consumption of fish from PFAS-contaminated water bodies; selecting cookware without PFAS non-stick coatings; choosing food packaging without PFAS grease-resistant treatments; and evaluating occupational PFAS exposures if relevant to the individual’s work history.
Biological PFAS elimination rates are compound-specific and relatively slow for most PFAS: PFOS has a biological half-life in humans of approximately 5 years; PFOA approximately 3-4 years; shorter-chain compounds eliminate more quickly (months to 1-2 years). This means that significant reduction in blood PFAS levels after exposure cessation requires years, not days or weeks—a reality that sets appropriate expectations for individuals hoping to see meaningful improvement on follow-up testing. Cholestyramine and other bile acid sequestrants have been investigated as potential interventions to accelerate PFAS elimination by interrupting enterohepatic recirculation, with modest evidence of modest efficacy—insufficient for routine clinical recommendation but an active research area.
Clinical Monitoring Recommendations
Individuals with documented high PFAS exposures—either through contaminated water history or occupational exposure—may benefit from baseline and periodic monitoring of health parameters associated with PFAS effects: lipid panels (total cholesterol, LDL, HDL, triglycerides), thyroid function tests (TSH, free T4), liver function tests (ALT, AST, GGT), kidney function (serum creatinine, eGFR, urine albumin-creatinine ratio), and fasting glucose/HbA1c. Clinical societies including the American College of Preventive Medicine and the International Society for Environmental Epidemiology are developing more specific clinical guidance; in the interim, shared decision-making between patients and clinicians—informed by available evidence and individual risk factors—represents the appropriate framework for managing PFAS health concerns in clinical practice.